Celularity Inc is a regenerative and cellular medicine company focused on developing placental-derived allogeneic cell therapies and biomaterial products for the treatment of degenerative diseases, aging-related conditions, cancer, and immune disorders... Show more
a blank check company, which focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, and reorganization
Industry Biotechnology
A.I.dvisor tells us that CELU and NVCT have been poorly correlated (+27% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CELU and NVCT's prices will move in lockstep.
| Ticker / NAME | Correlation To CELU | 1D Price Change % | ||
|---|---|---|---|---|
| CELU | 100% | -5.55% | ||
| NVCT - CELU | 27% Poorly correlated | +9.77% | ||
| LITS - CELU | 27% Poorly correlated | -9.94% | ||
| PRAX - CELU | 27% Poorly correlated | +4.56% | ||
| RNAC - CELU | 26% Poorly correlated | -2.53% | ||
| TELO - CELU | 26% Poorly correlated | +13.60% | ||
More | ||||
CELU saw its Momentum Indicator move below the 0 level on June 05, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 96 similar instances where the indicator turned negative. In of the 96 cases, the stock moved further down in the following days. The odds of a decline are at .
The Moving Average Convergence Divergence Histogram (MACD) for CELU turned negative on June 09, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CELU declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for CELU entered a downward trend on May 20, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where CELU's RSI Indicator exited the oversold zone, of 42 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 8 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CELU advanced for three days, in of 243 cases, the price rose further within the following month. The odds of a continued upward trend are .
CELU may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (10.672) is normal, around the industry mean (20.056). P/E Ratio (0.000) is within average values for comparable stocks, (35.868). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.677). CELU has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.038). P/S Ratio (0.725) is also within normal values, averaging (361.304).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. CELU’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CELU’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.